Results 31 to 40 of about 265 (112)

State of the art and perspectives of gene therapy in heart failure. A scientific statement of the Heart Failure Association of the ESC, the ESC Council on Cardiovascular Genomics and the ESC Working Group on Myocardial & Pericardial Diseases

European Journal of Heart Failure, Volume 27, Issue 1, Page 5-25, January 2025.
Abstract Gene therapy has recently become a reality in the treatment of cardiovascular diseases. Strategies to modulate gene expression using antisense oligonucleotides or small interfering RNA are proving to be safe and effective in the clinic. Adeno‐associated viral vector‐based gene delivery and CRISPR‐Cas9‐based genome editing have emerged as ...
Sophie Van Linthout, Konstantinos Stellos, Mauro Giacca, Edoardo Bertero, Antonio Cannata, Lucie Carrier, Pablo Garcia‐Pavia, Alessandra Ghigo, Arantxa González, Kristina H. Haugaa, Massimo Imazio, Luis R. Lopes, Patrick Most, Piero Pollesello, Heribert Schunkert, Katrin Streckfuss‐Bömeke, Thomas Thum, Carlo Gabriele Tocchetti, Carsten Tschöpe, Peter van der Meer, Eva van Rooij, Marco Metra, Giuseppe M.C. Rosano, Stephane Heymans   +23 more
wiley   +1 more source

Mitigating off‐target effects of small RNAs: conventional approaches, network theory and artificial intelligence

British Journal of Pharmacology, Volume 182, Issue 2, Page 340-379, January 2025.
Abstract Three types of highly promising small RNA therapeutics, namely, small interfering RNAs (siRNAs), microRNAs (miRNAs) and the RNA subtype of antisense oligonucleotides (ASOs), offer advantages over small‐molecule drugs. These small RNAs can target any gene product, opening up new avenues of effective and safe therapeutic approaches for a wide ...
Zoltán Bereczki, Bettina Benczik, Olivér M. Balogh, Szandra Marton, Eszter Puhl, Mátyás Pétervári, Máté Váczy‐Földi, Zsolt Tamás Papp, András Makkos, Kimberly Glass, Fabian Locquet, Gerhild Euler, Rainer Schulz, Péter Ferdinandy, Bence Ágg   +14 more
wiley   +1 more source

Non‐Viral RNA Delivery During Pregnancy: Opportunities and Challenges

Small, Volume 20, Issue 41, October 10, 2024.
RNA therapies have the potential to overcome the limitations of existing platforms for treating maternal‐fetal disorders. Here, the current state of RNA drug development is described for prenatal therapy and the most important bottlenecks that must be addressed for successful clinical translation.
Namit Chaudhary, Alexandra N. Newby, Kathryn A. Whitehead   +2 more
wiley   +1 more source

Pharmacokinetics and Pharmacodynamics of GalNAc‐Conjugated siRNAs

The Journal of Clinical Pharmacology, Volume 64, Issue 1, Page 45-57, January 2024.
Abstract Small interfering RNAs (siRNAs) represent a new class of drugs with tremendous potential for battling previously “undruggable” diseases. After nearly 2 decades of efforts in addressing the problems of the poor drug profile of naked unmodified siRNAs, this new modality has finally come to fruition, with 5 agents (patisiran, givosiran, lumasiran,
Guohua An
wiley   +1 more source

Zilebesiran: The First siRNA Drug Therapy for Hypertension

International Journal of Innovative Science and Research Technology (IJISRT)
Blood pressure, which includes ischemic heart disease, stroke, and chronic kidney disease, is the leading preventable cause of death from cardiovascular illnesses on a global scale. Worldwide, arterial hypertension ranks first among cardiovascular diseases (CVDs) and has done so for a long time. One of the first drugs to target hypertension using small
Zeba Sultana, Shaik Nikhath Faheem
openaire   +1 more source

Small Interfering RNA Therapeutics in Hypertension: A Viewpoint on Vasopressor and Vasopressor‐Sparing Strategies for Counteracting Blood Pressure Lowering by Angiotensinogen–Targeting Small Interfering RNA

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022
Priyanga Ranasinghe, Melisande L. Addison, David J. Webb   +2 more
doaj   +1 more source

Zilebesiran: an RNA therapeutic agent interfering with angiotensinogen synthesis

Cardiovascular Prevention and Pharmacotherapy
Hypertension remains a leading modifiable risk factor for cardiovascular morbidity and mortality worldwide, yet rates of blood pressure control remain suboptimal despite the availability of multiple classes of antihypertensive agents. Zilebesiran is a novel small interfering RNA therapeutic that targets hepatic angiotensinogen messenger RNA, offering a
openaire   +1 more source

Emerging Pharmacological Therapies for Hypertension

This review provides a general overview of the physiological effects and pharmacokinetic properties that affect the absorption, distribution, metabolism, and elimination of recently developed antihypertensive ...
Ashish Pagar, Ramanlal Kachave, Pritesh Mahajan, Kajal Baviskar   +3 more
core   +1 more source

Zilebesiran For Hypertension Treatment: An Overview

Hypertension remains one of the most common and serious global health problems, contributing significantly to cardiovascular and kidney diseases. Although several classes of antihypertensive drugs are available, many patients struggle with poor adherence and treatment resistance, making long-term blood pressure control difficult.
openaire   +1 more source

Highlights of cardiovascular disease prevention studies presented at the 2023 American Heart Association scientific sessions

Purpose of review: Focused review highlighting ten select studies presented at the 2023 American Heart Association (AHA) Scientific Sessions.Recent findings: Included studies assessed semaglutide and cardiovascular outcomes in overweight or obese ...
Virani, Salim S., Waldman, Carly E, Mehta, Sandeep, Minhas, Abdul Mannan Khan, Youngblood, Eventine, Sheikh, Sana, Hermel, Melody, Inam, Maha, Chiou, Andrew, Slipczuk, Leandro   +9 more
core   +1 more source